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Abstract The 7TM receptor, US28, encoded by human
cytomegalovirus binds a broad spectrum of endogenous CC
chemokines with sub-nanomolar affinity as determined in
homologous competition binding assays. We here find that
US28 also recognizes the membrane-associated CX3C chemo-
kine, fractalkine, with sub-nanomolar affinity (IC50 = 0.42 þ 0.09
nM). Importantly, although fractalkine could compete with high
affinity against the binding of CC chemokines, the secreted CC
chemokines were only able to compete for binding against
radioactive fractalkine with very low affinity. It is concluded that
US28, which is known to enhance cell-cell fusion processes
through interaction with an as yet unidentified, human cell-
specific factor, has been optimized by cytomegalovirus to
selectively recognize the membrane-associated fractalkine. It is
suggested that US28 expressed on the surface of infected cells
and possibly on the envelope of the virion is involved in transfer of
the virus from cell to cell.
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1. Introduction
Human cytomegalovirus encodes four 7TM, G-protein-
coupled receptors ^ US27, US28, UL33, and UL78 [1,2].
When the chemokine system was characterized at the molec-
ular level, it became clear that at least US27 and US28 were
homologues of human chemokine receptors. Accordingly,
US28 but not US27 was shown to bind several human CC
chemokines such as RANTES, MIP-1K, and MCP-1 [3,4].
Nevertheless, it was still unclear what bene¢t the virus could
have from expressing such receptors. Knock-out of the UL33
gene in the mouse and rat cytomegalovirus (CMV) indicated
that this receptor is important for the virulence of the virus.
UL33 was apparently involved in the targeting and/or repli-
cation of the virus in salivary glands, which is a crucial point
in the life cycle of the virus since spreading of virus from
individual to individual occurs through the saliva [5]. Since
US27 and US28 are only found in human CMV it has been
impossible to perform similar gene knock-out experiments
with these receptors in vivo. However, based on experiments
performed in vitro, it has been suggested that the ability of the
US28 receptor to bind and sequester a broad spectrum of CC
chemokines could be a mechanism by which the virus elimi-
nates these chemoattractants from the surroundings of in-
fected cells [6,7]. However, this does not appear to be a very
e⁄cient process and it will furthermore only work at a short
range.
Recently a new class of chemokines having three residues
between the ¢rst two cysteines and therefore named CX3C
was discovered. Fractalkine or neurotactin is as yet the only
known member of this CX3C chemokine ‘family’ [8,9]. Frac-
talkine is not a secreted chemokine but a membrane protein
consisting of a chemokine-like domain covalently associated
through a mucin-like stalk to a transmembrane segment. The
endogenous receptor for fractalkine is a previous orphan re-
ceptor called V28, now CX3CR1 [10], only distantly related to
the US28 receptor, as shown in Fig. 1. Nevertheless we ¢nd in
the present study that US28 is able to recognize the CX3C
chemokine, fractalkine, very selectively. US28 at the same
time functions as a broad-spectrum CC chemokine receptor.
However, none of the secreted CC chemokines can compete
with the binding of the radioactive CX3C chemokine domain
of fractalkine to the virally encoded US28 receptor. Since
enveloped viruses such as CMV get access to their target cells
through interaction of proteins in their membrane envelope
with membrane proteins on their target cells [11] it is sug-
gested that the highly specialized US28-fractalkine interaction
is involved in the cell to cell transfer of human CMV.
2. Materials and methods
2.1. Materials
The human CC chemokines MIP-1K, MIP-1L, MCP-1 and
RANTES were purchased from Peprotech, Rocky Hill, NJ. The
CX3C chemokine domain of fractalkine, corresponding to amino
acids 1^69 of the mature peptide as well as the DNA encoding the
US28 receptor were kindly provided by Timothy N.C. Wells, Serono,
Geneva. The ‘CX3C+stalk’, i.e. amino acids 1^317, corresponding to
the CX3C chemokine domain extended at the C-terminal end with the
mucin-like stalk but lacking the transmembrane segment was kindly
provided by Thomas J. Schall, ChemoCentryx, San Carlos, CA.
Monoiodinated 125I-MIP-1K, 125I-MIP-1L, 125I-RANTES and 125I-
MCP-1 were purchased from Amersham (Little Chalfont, UK). The
125I-labeled CX3C domain of fractalkine was prepared in-house using
Na125I (IMS30) (Amersham, Little Chalfont, UK) and the oxidizing
agent Iodo-Gen (1,3,4,6-tetrachloro-3K,6K-diphenylglycoluril) (Pierce,
Rockford, IL). The 125I-labeled CX3C chemokine was HPLC puri¢ed
before use.
2.2. Transfection and tissue culture
COS-7 cells were grown at 10% CO2 and 37‡C in Dulbecco’s modi-
¢ed Eagle’s medium 1885 supplemented with 10% fetal calf serum,
2 mM glutamine and 0.01 mg/ml gentamicin. Transfection of the
COS-7 cells was performed by the calcium phosphate precipitation
method [17].
2.3. DNA constructs
The US28 DNA was inserted into the pTEJ-8 expression vector [12]
and its sequence was con¢rmed (ALFexpress, Pharmacia Amersham).
The US28 clone used in the present study di¡ered by 25 nucleotides
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from the one deposited in GenBank, accession number L20501, which
was originally cloned from the VHL/E strain of human CMV. These
substitutions correspond to ¢ve relatively conservative amino acid
substitutions (D18E, E19D, L25F, K267R, and A346V), indicated
with asterisks in Fig. 1.
2.4. Binding experiments
COS-7 cells were transferred to 24 well culture plates 1 day after
transfection. The number of cells seeded per well was such as to
obtain 5^10% speci¢c binding of the added radioactive ligand. Two
days after transfection competition binding was performed on whole
cells for 3 h at 4‡C using 12 pM of either 125I-MIP-1K, 125I-MIP-1L,
125I-RANTES, 125I-MCP-1 or 125I-CX3C plus variable amounts of
unlabeled ligand in 0.5 ml of a 50 mM HEPES bu¡er, pH 7.4 sup-
plemented with 1 mM CaCl2, 5 mM MgCl2 and 0.5% (w/v) bovine
serum albumin. After incubation the cells were quickly washed four
times in 4‡C binding bu¡er supplemented with 0.5 M NaCl to reduce
unspeci¢c binding and interference caused by ligand dimerization.
Non-speci¢c binding was determined as the binding in the presence
of 0.1 WM unlabeled chemokine. Determinations were made in dupli-
cate.
2.5. Calculations
IC50 values were determined by non-linear regression and KD and
Bmax values were calculated from competition binding experiments
using the equations KD = IC503L and Bmax = B0(1+(KD/L)) using the
Inplot 4.0 software (GraphPad Software, San Diego, CA).
3. Results
The US28 receptor was expressed transiently in COS-7 cells
and competition binding experiments were performed on
whole cells at 4‡C using four di¡erent radioactively labeled
human CC chemokines as tracer: 125I-RANTES, 125I-MCP-1,
125I-MIP-1K, or 125I-MIP-1L. US28 bound all of these soluble
CC chemokines with almost similar, sub-nanomolar a⁄nity as
determined in homologous displacement experiments:
RANTES (IC50 = 0.50 nM), MCP-1 (IC50 = 0.76 nM), MIP-
1K (IC50 = 0.71 nM), and MIP-1L (IC50 = 0.72 nM) (Fig. 2 and
Table 1). This con¢rms previously published results using 125I-
MIP-1K, 125I-RANTES and 125I-MCP-1 [3,4,13]. Thus, in ho-
mologous binding experiments the human CMV-encoded
US28 receptor appears to be a broad-spectrum receptor for
the CC chemokines of its host.
When the CX3C chemokine domain of fractalkine was ap-
plied in competition binding assays against the radioactively
labeled RANTES, MCP-1, MIP-1K, or MIP-1L, the CX3C
domain, just like the CC chemokines, was able to bind to
the US28 receptor with sub-nanomolar a⁄nity, IC50 being
between 0.29 and 0.51 nM (Fig. 2 and Table 1). In all cases
the Hill coe⁄cient of the competition curve for the CX3C
domain was higher than the Hill coe⁄cient for the cor-
responding homologous displacement curve (Fig. 2 and
Table 1).
When the 125I-CX3C chemokine domain of fractalkine was
used as tracer, the CX3C domain itself displaced this with an
IC50 of 0.42 nM in homologous competition experiments,
corresponding closely to the IC50 values observed for the
CX3C domain in heterologous competition against the soluble
CC chemokines on the US28 receptor (Fig. 3A and Table 1).
Surprisingly, however, all the CC chemokines displayed a very
poor a⁄nity in heterologous competition binding experiments
against 125I-CX3C despite the high a⁄nity of these peptides
determined in homologous binding assays with the US28 re-
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Fig. 1. Serpentine diagram of the CMV-encoded US28 receptor. Residues that are identical in US28 and in the endogenous receptor for fractal-
kine, CX3CR1 (previously V28), but are not shared with the CC -chemokine receptors are indicated in white on black. Residues conserved
among CC chemokine receptors (CCR1, CCR2, CCR3, and CCR5) and US28 are indicated in black on gray. The US28 receptor used in this
study di¡ered from GenBank accession number L20501 in ¢ve amino acids, indicated with asterisks (see Section 2).
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ceptor (Fig. 3A,B). The heterologous competition curves for
the CC chemokines against 125I-CX3C were in fact each com-
posed of two components (Fig. 3A,B). Thus, 10^20% of the
125I-CX3C was displaced by the CC chemokines with the sub-
nanomolar IC50 values known from the homologous compe-
tition assays, whereas the remaining 85% was displaced by the
CC chemokines with IC50 values 100^1000-fold higher (Fig.
3A,B and Table 1).
It was not possible with the available tools to determine the
a⁄nity of the US28 receptor for the native fractalkine mole-
cule as such since both fractalkine and US28 are integral
membrane proteins. However, US28 did bind the CX3C
chemokine domain of fractalkine with high a⁄nity when it
was attached to its mucin stalk (IC50 = 2.8 nM) as determined
in competition against 125I-CX3C (Fig. 4). This a⁄nity is only
approximately seven times lower than the a⁄nity determined
for the free CX3C chemokine domain alone. Conceivably, a
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Fig. 2. Competition binding experiments with US28 using radioac-
tive CC chemokines as tracer. Binding was performed on whole
COS-7 cells transiently expressing US28 with either 125I-RANTES
(A), 125I-MIP-1L (B), 125I-MIP-1K (C) or 125I-MCP-1 (D). Competi-
tor ligands were the CC chemokines RANTES (O), MIP-1L (E),
MIP-1K (a), and MCP-1 (7) as well as the CX3C chemokine do-
main of fractalkine (F).
Fig. 3. Competition binding experiments with US28 using the radio-
active CX3C chemokine domain from fractalkine as tracer. Binding
was performed on whole COS-7 cells transiently expressing US28.
A: Competition binding curves for RANTES (O), MIP-1L (E),
MIP-1K (a), MCP-1 (7), and the CX3C chemokine domain of
fractalkine (F). B: The presumed high a⁄nity displacement mode
(IC50-high) and low a⁄nity displacement mode (IC50-low) for the
CC chemokines against the radioactive CX3C chemokine domain of
fractalkine are shown here for RANTES.
Fig. 4. Competition binding experiments with US28 using the radio-
active CX3C chemokine domain of fractalkine as tracer. Binding
was performed on whole COS-7 cells transiently expressing US28.
Competitor ligands were the CX3C domain (F) and the CX3C do-
main covalently associated with the mucin-like stalk of fractalkine,
CX3C+stalk (b).
T.N. Kledal et al./FEBS Letters 441 (1998) 209^214 211
multivalent interaction mode involving several molecules on
each side will in fact occur in an envisioned interaction be-
tween US28 located either on the envelope of a CMV virion
or on the surface of a CMV infected cell and fractalkine on
the surface of the presumed target cell.
4. Discussion
4.1. Selective US28-fractalkine recognition
The phenomenon that a receptor can function at the same
time as a broad-spectrum receptor and as a highly selective
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Table 1
Binding constants for selected CC chemokines and the CX3C chemokine domain of fractalkine on the human CMV-encoded US28 receptor us-
ing di¡erent radioactive ligands
Bmax (fmol/105 cells þ S.E.M.) IC50 in nM þ S.E.M. (n) ; (Hill coe⁄cient þ S.E.M.)
CX3C MIP-1K MIP-1L RANTES MCP-1
125I-CX3C 19 þ 3.6 0.42 þ 0.09 (6) 0.4/488 (7) 0.1/477 (4) 0.1/356 (5) 0.2/74 (4)
(1.24 þ 0.08)
125I-MIP-1K 14 þ 4.5 0.50 þ 0.21 (4) 0.71 þ 0.20 (5) ^ ^ ^
(1.23 þ 0.15) (0.88 þ 0.09)
125I-MIP-1L 32 þ 12 0.29 þ 0.09 (3) ^ 0.72 þ 0.26 (3) ^ ^
(1.34 þ 0.23) (0.89 þ 0.14)
125I-RANTES 41 þ 17 0.51 þ 0.17 (4) ^ ^ 0.50 þ 0.14 (4) ^
(1.17 þ 0.10) (0.69 þ 0.08)
125I-MCP-1 46 þ 7.4 0.37 þ 0.07 (5) ^ ^ ^ 0.76 þ 0.12 (5)
(1.05 þ 0.09) (0.84 þ 0.06)
Fold di¡erence 1 687 663 712 97
The US28 receptor was transiently expressed in COS-7 cells and competition binding experiments were performed on whole cells as described in the
text. Both homologous competition experiments ^ indicated in the diagonal of the table ^ and heterologous competition experiments against
125I-CX3C ^ indicated in the upper row ^ and heterologous competition for CX3C against the CC chemokines ^ indicated in the ¢rst column ^ were
performed. For the heterologous displacement of 125I-CX3C by CC chemokines IC50 values for both the minor, high a⁄nity displacement mode
and the major, low a⁄nity displacement mode are indicated (see Fig. 3) and consequently no Hill coe⁄cients are indicated in those cases. ‘Fold
di¡erence’ indicates the ratio between the IC50 value determined for the CC chemokines in homologous versus the major, low a⁄nity mode
determined in heterologous binding experiments.
Fig. 5. Diagram of proposed membrane protein interactions in the binding and fusion process between various virus and target cells. A: Left
panel: HIV enveloped protein gp120 binding to CD4 plus one of several chemokine receptors, here CXCR4. Middle panel: targeting of vesicu-
lar stomatitis virus (VSV) to HIV-infected target cells expressing gp120 after substitution of the VSV normal spike protein G with CD4 and
CXCR4 [24,25]. Right panel: proposed target cell binding of CMV virion through interaction of its US28 chemokine receptor to the membrane
associated fractalkine with its CX3C chemokine domain. B: Proposed involvement of the US28-CX3C binding in the dissemination of the virus
via tight cell-cell interactions/fusion. CMV-infected leukocytes express US28 in their cell membrane and could facilitate the interaction of the in-
fected cells with a target endothelial cell expressing fractalkine with its CX3C chemokine domain.
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receptor has previously been studied especially in the tachy-
kinin system. The NK1 receptor, which originally was consid-
ered to be highly selective for the neuropeptide, substance P,
was recently found to bind basically all tachykinin pep-
tides with sub-nanomolar a⁄nity [14,15]. Moreover, all these
peptides could function as agonists on the receptor. This ob-
servation could explain, for example, the stimulatory func-
tion of NKA at sites in the CNS where no ‘normal’ NK2
receptor was present. The problem had previously been
that NKA and other non-substance P tachykinins competed
only very poorly against radioactive substance P [14] ^ just
as the CC chemokines all compete poorly against the radio-
active CX3C on US28 in the present study. Also in the
case of the NK1 receptor, the ‘selectively’ recognized ligand,
in this case substance P, competes readily against the non-
substance P tachykinin peptides [14] ^ just as fractalkine
competes readily against the secreted CC chemokines on
US28.
The structural or cell biological reason for this non-classical
competitive behavior of di¡erent ligands ^ usually agonists ^
for the same receptor is still unclear [15]. However, it has been
suggested that it may be related to the interaction of the
receptor with di¡erent G-proteins, which may be compart-
mentalized in the cell. Another possibility is that monomeric
versus dimeric forms of the receptor could selectively recog-
nize certain G-proteins and/or ligands. Whatever the structur-
al reason, the phenomenon appears to be observed in many
di¡erent 7TM receptor systems.
4.2. Is fractalkine a target cell receptor for human CMV?
The life cycle of CMV within its host is complicated and
has still not been totally clari¢ed. Most certainly it involves
viral transfer between several cell types. A number of not very
well de¢ned proteins of various molecular sizes have been
suggested as target cell receptors for human CMV
[11,16,17]. But none of these have yet been generally accepted.
Both fractalkine and US28 are located appropriately for being
involved in cell targeting and/or cell entry of CMV. Thus,
fractalkine is expressed on, for example, endothelial cells as
well as several other putative target cells for CMV [8,9,18].
US28 is expressed on the surface of CMV infected cells
[6,7,19,20]. And ^ although it has not yet directly been
demonstrated for US28 ^ two of the other CMV-encoded
7TM receptors, UL33 and US27, have been shown by im-
munochemistry to be located in the envelope membrane of
human CMV ([2] and H. Browne, personal communica-
tion). Interestingly, although US28 can recognize a number
of CC chemokines with high a⁄nity, none of these secreted,
endogenous chemokines can in fact hinder the binding
of US28 to the membrane-associated fractalkine, i.e. they
cannot block the hypothetical virus entry/transfer process
(Fig. 5).
The US28 receptor co-expressed with CD4 has recently
been shown to be able to mediate cell fusion with HIV-1
gp120 expressing cells [21,22]. Importantly, US28 can function
as a co-receptor mediating cell fusion together with not only
CD4 but also, for example, envelope proteins from other vi-
ruses such as vesicular stomatitis virus (VSV) and human T-
cell lymphoma virus-1 (HTLV-1) [22]. It was concluded by
Plesko¡ and coworkers that US28 enhanced the cell fusion
process mediated by di¡erent viral proteins through a speci¢c
interaction with an as yet unidenti¢ed membrane protein
found on human cells [22]. We would suggest that this mem-
brane protein is fractalkine and that the US28-fractalkine in-
teraction has been optimized as part of the cell-cell transfer
mechanism for CMV in man (Fig. 5B). Chemokine 7TM re-
ceptors expressed on the target cells are obviously already
known to be e⁄cient coreceptors in the cell entry process
for HIV-1 [23]. It is known from genetically engineered rhab-
dovirus, e.g. VSV, that the glycoprotein-7TM receptor com-
plex functions equally well in cell entry when the 7TM is ex-
pressed on the virus and the viral envelope protein ‘ligand’ is
expressed on target cells [24,25]. Thus, we here suggest that
such a system has already been developed naturally in human
CMV (Fig. 5).
In the CMV-target cell interaction several proteins on
each side are probably involved just as is the case for
many other viral cell entry processes [11]. Thus, although
US28 can assist in the cell fusion process with human
cells ^ supposedly expressing fractalkine ^ cell fusion does
not take place in these in vitro systems without the co-expres-
sion of additional known viral envelope proteins, for example
proteins from HIV-1, VSV, or HTLV-1 [22]. Moreover,
human CMV in which US28 has been genetically eliminated
can still infect tissue culture cells equally e⁄cient as wild-type
virus, e.g. under the special circumstances normally used in
vitro [6,7]. Although we here propose that fractalkine
may function as a target cell receptor for human CMV, it
should be noted that several other proteins having character-
istics signi¢cantly di¡erent from those of fractalkine have
previously been suggested to be receptors for CMV [11,16,
17,26].
4.3. Why is US28 also a broad-spectrum CC chemokine
receptor?
Not only membrane proteins as such but also heparan sul-
fate has been suggested to be involved as target cell receptors
for human CMV [11]. In the present context, this could be
interesting since chemokines are known to bind to glycosami-
noglycans [27,28]. An interesting, albeit speculative possibility
could be that US28 recognition of glcosaminoglycan-bound
CC chemokines is involved in this process.
A second possibility could be that the binding of the en-
dogenous soluble secreted CC chemokines could serve to pro-
tect the US28 receptor from being recognized as a foreign
molecule by the immune system. Chemokines are relatively
large ligands, which could rather e¡ectively shield the recep-
tor.
Finally, US28-CC chemokine interaction may be involved
in tissue targeting of the virus. In this connection it may be
important that CMV at a certain stage in its life cycle infects
neutrophil granulocytes [29,30], which normally respond only
to CXC chemokines and not to CC chemokines. Thus, since
US28 functions as a signaling G-protein-coupled receptor in
CMV-infected cells in vitro [20], it is possible that the endog-
enous granulocytes after infection with CMV become respon-
sive to CC chemokines and thereby obtain the signalling ma-
chinery for transporting the virus to a supposedly appropriate
CC-secreting tissue.
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